How Clinical Trials Work—From Lab to Pharmacy
Clinical trials are the rigorous, multi-phase process every new drug must survive before reaching patients. Here is how the system works, why it takes over a decade, and what each phase actually tests.
Why Every Drug Must Run the Gauntlet
Before any new medicine reaches a pharmacy shelf, it must survive one of the most demanding evaluation systems ever devised. Clinical trials — the structured experiments that test whether a treatment is safe and effective in humans — are the backbone of modern medicine. The process is long, expensive, and deliberately unforgiving: only about one in seven drug candidates that enter clinical testing ever wins regulatory approval.
Before Humans: The Preclinical Stage
Drug development begins years before a single patient volunteers. Scientists first identify a promising compound in the laboratory, then test it in cell cultures and animal models to assess basic safety and biological activity. According to the U.S. Food and Drug Administration, only candidates that demonstrate an acceptable safety profile in preclinical work may advance to human testing. Even so, the vast majority of molecules screened in early research never make it this far — roughly one in 20,000 to 30,000 compounds discovered in the lab ultimately becomes an approved drug.
The Four Phases Explained
Phase I — Is It Safe?
A small group of 20 to 80 healthy volunteers receives the drug for the first time. The goal is not to cure disease but to map the drug's behaviour in the human body: how it is absorbed, metabolized, and excreted, and at what dose side effects appear. Researchers gradually increase the dose to find the maximum amount the body can tolerate. Phase I typically lasts several months.
Phase II — Does It Work?
If Phase I shows acceptable safety, researchers recruit 100 to 300 patients who actually have the target disease. This phase generates the first real evidence of efficacy. Most Phase II studies are randomized and double-blind — meaning patients are assigned by chance to receive either the experimental drug or a placebo, and neither the patient nor the doctor knows which is which. This design, widely regarded as the gold standard of medical evidence, minimizes bias and the power of suggestion. Phase II usually takes one to three years.
Phase III — Proving It at Scale
Phase III trials expand dramatically, enrolling several hundred to 3,000 or more participants across multiple hospitals and countries. The primary aim is to confirm effectiveness, monitor side effects in a diverse population, and compare the new treatment against existing standard therapies. According to the National Institutes of Health, only about 25 to 30 percent of drugs that enter Phase III ultimately pass. These large-scale trials can run for several years and cost hundreds of millions of dollars.
Phase IV — Watching After Approval
Even after a drug reaches the market, monitoring continues. Phase IV post-market surveillance tracks long-term effects and rare adverse events across the general population — sometimes involving tens of thousands of patients over many years. If serious problems emerge, regulators can restrict or withdraw the drug.
How Long Does It All Take?
The median clinical development timeline — from the first Phase I dose to regulatory approval — is approximately eight years, according to research published in Nature Communications. When preclinical research is included, the full journey from laboratory discovery to pharmacy shelf typically spans 12 to 15 years. Oncology drugs face an even steeper road: their median clinical trial duration exceeds 13 years, and only about 2.4 percent of cancer drugs entering Phase I ultimately win approval.
Who Regulates the Process?
In the United States, the FDA oversees every stage. In Europe, the European Medicines Agency plays a similar role. The United Kingdom is currently overhauling its own framework: new clinical trial regulations taking effect on 28 April 2026 will streamline the approval process by allowing researchers to obtain ethical and regulatory clearance through a single combined application — the biggest change in British trial regulation in two decades.
Why It Matters
The system's deliberate caution exists for good reason. History is littered with examples of drugs that seemed promising but caused harm once given to larger or more diverse populations. The multi-phase structure ensures that each step answers a specific question — safety, efficacy, real-world performance — before millions of patients are exposed. It is slow, expensive, and imperfect, but clinical trials remain the most reliable method humanity has for separating treatments that work from those that do not.
